TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06314503

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WEAKID
Description: Six treatments over the course of two weeks with the WEAKID system:~* Week 1 (without the sorbents)~  * Day 1: four-hour treatment~ * Day 2: eight-hour treatment~ * Day 3: eight-hour treatment~* Week 2 (with the sorbents)~  * Day 1: four-hour treatment~ * Day 2: eight-hour treatment~ * Day 3: eight-hour treatment
Study: NCT05020548

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: peak inspiratory pressure 10 cmH2O
Description: pressure controlled mask ventilation with peak inspiratory pressure of 10 cmH2O

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: peak inspiratory pressure 15 cmH2O
Description: pressure controlled mask ventilation with peak inspiratory pressure of 15 cmH2O

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: peak inspiratory pressure 20 cmH2O
Description: pressure controlled mask ventilation with peak inspiratory pressure of 20 cmH2O
Study: NCT04849988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP-450
Description: ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP-450
Description: ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP-450
Description: ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride, sterile, unpreserved, USP/Ph.Eur.
Study: NCT05928780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A1:SG with SHR3680
Description: SG 10mg/kg d1, 8；SHR3680 240mg qd，3 weeks is a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A2:SG
Description: SG 10mg/kg d1, 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B1:SG with SHR1210
Description: SG 10mg/kg， d1, 8；SHR1210 200mg，d1，q3w；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B2:SG
Description: SG 10mg/kg， d1, 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1:SG with SHR3162
Description: SG 10mg/kg d1, 8；SHR3162，150mg，QD ，3 weeks is a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C2:SG
Description: SG 10mg/kg d1, 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1:SG with VEGFRI
Description: SG 10mg/kg，d1, 8；BP102 15mg/kg，d1，3 weeks is a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D2:SG
Description: SG 10mg/kg d1, 8
Study: NCT06090149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHASE 1 Lowenstein medical BiLevel Prisma 25ST device: withount oxygen support.
Description: The patient will be invited to enter the study's first phase using the Lowenstein medical BiLevel Prisma 25ST device without additional oxygen support. The study will be conducted within 1-3 days. If patients fail to achieve proper blood oxygen saturation without oxygen supplementation, patient will be selected to proceed to the next step - oxygen-enriched positive airway pressure intervention~During monitoring TA, RR, HR, SpO2, as well as CO2 in both exhales/inhales and transcutaneous positions will be measured by Lowenstein Medical Sonata and Sentec device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHASE 2. Continous/Bilevel positive airway presure with additional oxygen support by Devilbiss 525 KS oxygen concentrator
Description: The patient will be invited to enter the third phase of the study with rapid oxygen titration. Titration occurs in an inpatient department where the patient is connected to the Lowenstein medical BiLevel Prisma 25ST device with oxygen support during the daytime. As part of the study, the patient will be supplied with oxygen by Devilbiss 525 KS oxygen concentrator at a dosing interval of 1-10 L/min. Every 2 hours oxygen support will be increased by 2L/min.~During monitoring TA, RR, HR, SpO2, and CO2 in both exhales/inhales and transcutaneous positions will be measured by Lowenstein Medical Sonata and Sentec device.
Study: NCT06165900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)
Description: Adebrelimab plus radiotherapy phase: radiotherapy was started on the day of the second cycle of adebrelimab administration every other day for 3 fractions; Adebrelimab plus chemotherapy phase: starting within 3-5 weeks after completion of radiotherapy, every 3 weeks for 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)
Description: adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)
Study: NCT04933825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET-02
Description: A conditioning therapy with cyclophosphamide and fludarabine will be conducted before ET-02 injection.
Study: NCT05887297

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for insomnia
Description: CBT-I is a multi-component, evidence-based intervention which incorporates both cognitive and behavioural techniques to address symptoms of insomnia, aiming to improve satisfaction with the duration and quality of sleep by reducing trouble falling and/or staying asleep. CBT-I will be delivered over 4 weekly 1-hour sessions, via videoconferencing. Session 1 will include psychoeducation about sleep (the relationship between sleep and mental health, the '3P' model of insomnia), and begin to explain components of CBT-I (sleep restriction and relaxation). Session 2 will reinforce previous learning about these components and introduce stimulus control. Session 3 will introduce sleep hygiene and its importance in preventing poor sleep. Session will 4 discuss cognitive therapy techniques and relapse prevention.
Study: NCT05369871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop system
Description: Closed-loop system consisting of a terminal including the Diabeloop algorithm that is associated with the Dexcom G6 CGM and the Accu-Chek Insight insulin pump.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop system
Description: Closed-loop system consisting of a terminal including the Diabeloop algorithm that is associated with the Dexcom G6 CGM and the Accu-Chek Insight insulin pump.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open-loop system
Description: Open-loop system consisting of a terminal without the Diabeloop algorithm that is associated with the Dexcom G6 CGM and the usual insulin pump.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open-loop system
Description: Open-loop system consisting of a terminal without the Diabeloop algorithm that is associated with the Dexcom G6 CGM and the usual insulin pump.
Study: NCT04927533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ronnie Gardiner Method
Description: The Ronnie Gardiner Method (RGM), developed in 1993 by Swedish jazz drummer Ronnie Gardiner, is a promising multimodal, music-based intervention with potential to stimulate and improve several cognitive functions, motor skills, reading and speech skills and social interaction. RGM participants are required to follow (what is known as) choreoscores. This is a visual representation of the sequence of movements using four unique symbols. Each symbol represents a body half via color (red = left side, blue = right side) and the use of a body part via shape (the symbols resemble hands or feet). In addition, each movement has a specific name, based on drum sounds, which must be pronounced simultaneously. The exercises are guided by trained 'RGM-practitioners'. The course and difficulty of the session can be adapted in different ways by the RGM Practitioner, according to the capabilities of the participants.
Study: NCT06433375

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical debulking of periapical tissues
Description: Non surgical debulking of periapical tissues

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Growth hormone application
Description: Growth hormone application during non-surgical root canal treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical debulking of periapical tissues with growth hormone application
Description: Non-surgical debulking of periapical tissues with growth hormone application during non-surgical root canal treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical debulking of periapical tissues with growth hormone application
Description: Non-surgical debulking of periapical tissues with growth hormone application during non-surgical root canal treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical debulking of periapical tissues with growth hormone application
Description: Non-surgical debulking of periapical tissues with growth hormone application during non-surgical root canal treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal treatment
Description: Teeth undergo conventional root canal treatment without any additional intervention
Study: NCT05381623

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simplified suture-less approach
Description: Immediately after the harvest of a free gingival graft from hard palate, at least a half carpule of local anesthetic (articaine 4% 1:100.000 epinephrine) will be infiltrated within the apical border of the harvesting site and another half mesially and distally to the harvesting site. At the end of the mucogingival procedure, the donor site will be evaluated to inquire regarding the presence of a competent coagulum over the wound area. In such a case, no additional procedure will be performed at the recipient site.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Application of hemostatic sponges and compressive sutures
Description: Immediately after the harvest of a free gingival graft from hard palate, hemostatic collagen sponges will be applied over the harvesting site and a series of tooth suspended external mattress sutures (PGA 5/0) will be applied over the area, in order to provide a compressive effect.
Study: NCT05896956

Intervention type: OTHER
Intervention: no interventions
Description: no interventions
Study: NCT06029036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide+ADT
Description: Drug: Darolutamide~Darolutamide 600 mg, (two 300 mg tablets) administered orally twice daily. Swallow tablets whole. Take Darolutamide with food.~Drug: ADT GnRH agonist per physicians' choice, orchiectomy is excluded
Study: NCT02232100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attentional bias modification training (AMG)
Description: Attentional bias modification, administered via an internet-delivered visual-probe task that trains attention away from pain-related information

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attentional bias modification training (AMG)
Description: Attentional bias modification, administered via an internet-delivered visual-probe task that trains attention away from pain-related information

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attentional bias placebo (ACG)
Description: Attentional bias placebo, administered via an internet-delivered visual-probe task that does not train attention either away or towards pain-related information

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attentional bias placebo (ACG)
Description: Attentional bias placebo, administered via an internet-delivered visual-probe task that does not train attention either away or towards pain-related information
Study: NCT05400876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2618 injection
Description: TQB2618 injection is an inhibitor of T cell immunoglobulin and mucin domain-containing protein 3 (TIM3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab injection
Description: Penpulimab is an inhibitor of programmed cell death protein 1 (PD-1)
Study: NCT06485375

Intervention type: DIAGNOSTIC_TEST
Intervention: EMG
Description: Disposable bipolar surface electrodes will be used. The patient's skin will be clean with cotton gauze soaked in alcohol before electrodes placement to reduce skin impedance. The operator will palpate the muscle belly while the patient clenches his teeth and will position surface electrodes in parallel to the muscular fibres. Doing so the position of the electrodes results as follows: Masseters electrodes will be fixed parallel to the exocanthion-gonion line and with the upper pole of the electrode under the tragus-labial commissural line. Temporalis electrodes will be positioned along the anterior margin of the muscle (corresponding to the frontoparietal suture). Suprahyoid muscles electrodes will be placed in the submental area nearly 1 cm posterior to the mental symphysis, paramedian to the midline and lightly diverging. A reference electrode will be applied to the forehead of the patient.
Study: NCT05493007

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sandbag motion style acupuncture treatment
Description: Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Korean medical treatment
Description: acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Korean medical treatment
Description: acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine.
Study: NCT05353764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scalp nerve block combined with intercostal nerve block using 0.5% ropivacaine
Description: Participants randomized to the SNB group will receive general anesthesia combined with scalp nerve block and intercostal nerve block with 0.5% ropivacaine, which was performed exclusively by an attending anesthesiologist.An attending anesthesiologist will select the site of SNB based on the surgical incision site. Scalp nerve was blocked including greater occipital nerve (2-3ml), superficial temporal nerve (2-3ml), trochlear nerve (2-3ml) and supraorbital nerve (2-3ml). The total volume in scalp nerve block will not exceed 10 ml.Ultrasound-guided unilateral ICNB will be performed at the level of T4-T5 next to the sternum.10-15ml of 0.5% ropivacaine will be injected into the intercostal spaces where incision locates after negative aspiration.
Study: NCT06139003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3d Printed implant
Description: Occlusal stability was evaluated using occlusense device by charting amount and distribution of force over dental arch in percentage

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventionally constructed implant
Description: Occlusal stability was evaluated using occlusense device by charting amount and distribution of force over dental arch in percentage
Study: NCT05155306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894, intended Commercial Formulation (iCF) (T)
Description: Test Treatment (T)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894, intended Commercial Formulation (iCF) (T)
Description: Test Treatment (T)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894, Trial Formulation 2 (TFII) (R)
Description: Reference Treatment (R)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894, Trial Formulation 2 (TFII) (R)
Description: Reference Treatment (R)
Study: NCT05274711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration training
Description: The participants will be instructed to stand on the vibration platform bare footed and distribute their weight evenly on both feet (fig 3). Next, they will be asked to do a head and neck retraction while looking forward with their knees at 30 degrees of flexion. In order to prevent fatigue in the subject's cervical area due to holding their head and neck in retraction, they will be asked to hold this position for 15 seconds then rest for 5 seconds. Since each set will last 60 second this allowed the subjects to do 3 retractions in each set. In total each subject will perform 15 retractions during the training. The subjects will experience a vertical vibration at a frequency and amplitude of 30 Hz and 4 mm during the sets (Salami et al., 2018).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical treatment
Description: Posturalcorrectionexercisesintheformofstretchingandstrengthening exercise. Manual stretching exercises as passive stretch to (upper trapezius, levator scapulae, sub occipitalis, scalene, sternocleidomastoid, and pectoralis major muscles), 30 seconds of 3-5 repetitions for each muscle, followed by 30 seconds of rest, as well as isotonic exercises (to strength deep neck flexors and scapular retractor muscles) 3 sets of 12 repetitions each with a 6 second hold in between, with a 1-2-minute rest between sets (Kisner. and Colby 2012).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical treatment
Description: Posturalcorrectionexercisesintheformofstretchingandstrengthening exercise. Manual stretching exercises as passive stretch to (upper trapezius, levator scapulae, sub occipitalis, scalene, sternocleidomastoid, and pectoralis major muscles), 30 seconds of 3-5 repetitions for each muscle, followed by 30 seconds of rest, as well as isotonic exercises (to strength deep neck flexors and scapular retractor muscles) 3 sets of 12 repetitions each with a 6 second hold in between, with a 1-2-minute rest between sets (Kisner. and Colby 2012).
Study: NCT06123520

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ho-YAG Laser Visual internal urethrotomy
Description: the operations will be performed by an expert surgeon and operative time will be considered. The procedure will be performed under spinal or general anaesthesia in lithotomy position. Antibiotic will be given just before and 12 h after procedure and continued for next 5 days.~Normal saline will be used for irrigation during the procedure. A Holmium laser at an energy of 1,200 to 2.000 mJ with a frequency of 10 to 15 Hz will be used By use of a 22 F cystoscope and Ho:YAG laser, the stricture site will be completely incised while sparing healthy mucosa. a fiber will be positioned about 1 mm away from the tissue and the laser will be fired.~An 18 F silicone Foley catheter will be left in the urethra at the end of the procedure. urethral catheter removal and voiding trial will be given at postoperative Day 7.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ho-YAG Laser Visual internal urethrotomy combined with intralesional submucosal injection of Paclitaxel
Description: The investigators will follow the same interversion protocol in the first group then paclitaxel is going to be injected via Williams cystoscopic injection needle (5 F size and 23 G needle size) through the cystoscope after laser ablation of the stricture in the submucosa with an assumed dose of 3.5µg/mm2 (reaching a urethral diameter of 30 Fr and a total length of 2 cm a total dose of 2.2 mg divided along 3 injection is to be injected). the dose is divided at 12,4 and 8 o'clock respectively along the length of the stricture.~An 18 F silicone Foley catheter will be left in the urethra at the end of the procedure. urethral catheter removal and voiding trial will be given at postoperative Day 7.
Study: NCT05524103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALMB-0166
Description: A single dose of ALMB-0166 injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALMB-0166
Description: A single dose of ALMB-0166 injection.
Study: NCT05584475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Awareness Practices (MAPs)
Description: MAPs is an 8-session, group-based approach for individuals with ADHD to improve attentional difficulties and related impairments by enhancing attending to and accepting experiences in the present moment. Sessions typically last between 60 and 90 minutes, though may last up to 120 minutes.
Study: NCT05717699

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-TD-nsIL12
Description: After stereotactic biopsy, the Ommaya reservoir will be inserted through the biopsy channel and two injections of Ad-TD-nsIL12 will be delivered after surgery by Ommaya reservoir (with an interval of 3days). The interval between following injections in the subsequent treatment period will be 3 weeks ±4 days. The assigned dose for each patient will be 3x10\^9vp, 1x10\^10vp or 3x10\^10 vp suspended in 1 ml NS according to cohort design.
Study: NCT05764044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin, gemcitabine
Description: Two additional cycles of cisplatin-based adjuvant chemotherapy 50mg/m2 D1 and gemcitabine 1000mg/m2 D1 and D8 at every 21 days.

Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up
Description: Patients will be followed with plasma cfDNA-HPV, computed tomography (CT) scan of the thorax and magnetic resonance (MRI) of abdomen and pelvis and clinical and gynecological examination at every four months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up
Description: Patients will be followed with plasma cfDNA-HPV, computed tomography (CT) scan of the thorax and magnetic resonance (MRI) of abdomen and pelvis and clinical and gynecological examination at every four months.
Study: NCT05909475

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GKEX
Description: GKEX group. Probiotic capsules contain 10 billion CFU (colony forming units) of GKEX, , 2 caps daily use.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsule contains microcrystalline cellulose, 2 caps daily use.
Study: NCT05231642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Interventional
Description: Individualised postprandial glucose and vascular risk responses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Interventional
Description: Individualised postprandial glucose and vascular risk responses